

Practitioner's Docket No. : MPI90-002CP2DV1CNBCN3M

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

031283 U.S. PTO  
10/712332



111303

**NEW APPLICATION TRANSMITTAL**

Transmitted herewith for filing is the patent application of  
Inventor(s): David L. Wolf and Uma Sinha

For: AGENTS AFFECTING THROMBOSIS AND HEMOSTASIS

**1. Type of Application**

This new application is for a(n)

- Original (nonprovisional)  
 Design  
 Plant  
 Divisional.  
 Continuation.  
 Continuation-in-part (C-I-P).

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- deposited with the United States Postal Service in an envelope addressed to the Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

- with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"  
Mailing Label No. EV312194647US

**TRANSMISSION**

- transmitted by facsimile to the Patent and Trademark Office.

  
Signature  
Sean Hunziker/Carolyn Willey

(type or print name of person certifying)

Date: November 13, 2003

**\*WARNING:** *Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b).*

*"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.*

**Practitioner's Docket No. : MPI90-002CP2DV1CNBCN3M**

**2. Benefit of Prior U.S. Application(s) (35 U.S.C. Sections 119(e), 120, or 121)**

- The new application being transmitted claims the benefit of prior U.S. Application Number 09/671,346 filed September 27, 2000.

**3. Maintenance of Copendency of Prior Application**

- A.  Extension of time in prior application

- B.  Conditional Petition for Extension of Time in Prior Application

*(complete this item, if previous item not applicable)*

- A conditional petition for extension of time is being filed in the pending **prior** application.

- A copy of the conditional petition filed in the prior application is attached.

**4. Abandonment of Prior Application (if applicable)**

- Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.

**Notification in Parent Application of This Filing**

- A notification of this continuation is being filed in the parent application from which this application claims priority under 35 U.S.C. Section 120.

**5. Papers Enclosed**

**Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application**

47 Pages of Specification, including

45 Pages of Description

1 Pages of Claims

1 Page of Abstract

15 Sheet of Drawings (Figure(s) 1, 2, 3, 4, 5A, 5B, 6, 7A, 7B, 7C, 7D, 8A, 8B, 8C, 8D, 9, 10, 11, 12A, 12B, 13, 14, and 15

- The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. Section 1.84(b).

- Formal

- Informal

**Practitioner's Docket No. : MPI90-002CP2DV1CNBCN3M**

**6. Additional Papers Enclosed**

- Information Disclosure Statement (37 C.F.R. Section 1.98)
- Form PTO-1449 (PTO/SB/08A and 08B)
- Citations
- Declaration of Biological Deposit
- 14 pages of paper copy of Sequence Listing (37 CFR Section 1.821-1.823), Diskette containing computer readable form of Sequence Listing (37 CFR Section 1.821(e) and 1.824), and 4 pages of Submission of "Sequence Listing," Computer Readable Copy, and/or Amendment Pertaining Thereto for Biotechnology Invention Containing Nucleotide and/or Amino Acid Sequence (37 CFR Section 1.821(f))
- Authorization of Attorney(s) to Accept and Follow Instructions from Representative
- Special Comments
- Other:

**7. Declaration or Oath (including power of attorney)**

- (6 pages) A copy of the executed Combined Declaration and Power of Attorney signed by David L. Wolf as filed in USSN 09/671,346 filed September 27, 2000, is enclosed. A copy of the executed Combined Declaration and Power of Attorney signed by Uma Sinha as filed in USSN 09/671,346 filed September 27, 2000, is enclosed.

**8. Assignment**

- A copy of two assignments of the invention to COR Therapeutics, Inc. dated May 10, 1994 recorded at Reel 7079, Frame 0652 as filed in continuation-in-part application USSN 08/268,003 filed June 29, 1994 (are enclosed) and a copy of the Certificate of Merger of Ownership merging COR Therapeutics, Inc. into Millennium Pharmaceuticals, Inc. dated June 10, 2002 recorded at Reel 012977, Frame 0516 as filed in Application No. 09/671,346 filed September 27, 2000 is enclosed.

**9. Related Applications**

Amend the specification by deleting after the Title the Cross-Reference to Related Applications paragraph and inserting, the following:

This application is a continuation of Application Serial No. 09/671,346 filed September 27, 2000 which is a continuation of Application Serial No. 09/362,207 filed July 28, 1999 (abandoned), which is a continuation of Application Serial No. 09/016,403 filed January 1998 (Patent No. 5,968,897), which is a divisional of Application Serial No. 08/469,301 filed June 6, 1995 (Patent No. 5,837,679), which is a divisional of Application Serial No. 08/268,003 filed June 29, 1994 (Patent No. 5,583,107), which is a continuation-in-part of Application Serial No. 08/249,777 filed May 26, 1994 (Patent No. 5,597,799), which is continuation of Application No. 07/808,329 filed December 16, 1991 (abandoned), which is a continuation-in-part of Application No. 07/578,646 filed September 4, 1990 (Patent No. 5,278,144)

Practitioner's Docket No. : MPI90-002CP2DV1CNBCN3M

9. **Fee Calculation** (37 C.F.R. Section 1.16)

A.  Regular application

CLAIMS AS FILED					
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. Section 1.16(a) \$770.00
Total Claims (37 C.F.R. Section 1.16(c))	5	- 20 =	0	\$18.00	\$0.00
Independent Claims (37 C.F.R. Section 1.16(b))	3	- 3 =	0	\$86.00	\$0.00
Multiple Dependent Claim(s), if any (37 C.F.R. Section 1.16(d))	0	\$290.00			\$0.00

**Filing Fee Calculation** **\$770.00**

- Amendment canceling extra claims is enclosed.
- Amendment deleting multiple-dependencies is enclosed.
- Fee for extra claims is not being paid at this time.

**Practitioner's Docket No. : MPI90-002CP2DV1CNBCN3M**

**10. Method of Payment of Fees**

- Check in the amount of \$\_\_\_\_\_.
- Charge Account No. 501668 in the amount of \$770.00

A duplicate of this transmittal is attached.

**11. Authorization to Charge Additional Fees**

- The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 501668.
- 37 C.F.R. Section 1.16(a), (f) or (g) (filing fees)
- 37 C.F.R. Section 1.16(b), (c) and (d) (presentation of extra claims)
- 37 C.F.R. Section 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)
- 37 C.F.R. Section 1.17(a)(1)-(5) (extension fees pursuant to Section 1.136(a)).
- 37 C.F.R. Section 1.17 (application processing fees)
- 37 C.F.R. Section 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. Section 1.311(b))

**12. Instructions as to Overpayment**

- Credit Account No. 501668.
- Refund

**13. Correspondence Address**


Direct all future correspondence to:

Customer Number 30405  
OR  
Intellectual Property Department  
MILLENNIUM PHARMACEUTICALS, INC.  
75 Sidney Street  
Cambridge, MA 02139

November 13, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By

  
Jean M. Silveri

Registration No. 39,030

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-679-7336

Faxsimile - 617-551-8820

- Statement Where No Further Pages Added

- This transmittal ends with this page.